candesartan has been researched along with Cancer of Prostate in 6 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Excerpt | Relevance | Reference |
---|---|---|
"The effect of ARBs on prostate cancer in experimental models compared with meta-analysis data from clinical trials is conflicting." | 1.40 | Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis. ( Al-Azayzih, A; Alhusban, A; Fagan, SC; Gao, F; Goc, A; Somanath, PR, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alhusban, A | 1 |
Al-Azayzih, A | 1 |
Goc, A | 1 |
Gao, F | 1 |
Fagan, SC | 1 |
Somanath, PR | 1 |
Takahashi, S | 1 |
Uemura, H | 4 |
Seeni, A | 1 |
Tang, M | 1 |
Komiya, M | 1 |
Long, N | 1 |
Ishiguro, H | 3 |
Kubota, Y | 4 |
Shirai, T | 1 |
Ikeda, N | 1 |
Nakaigawa, N | 3 |
Ouchi, H | 1 |
Yamagishi, T | 1 |
Noguchi, K | 2 |
Hasumi, H | 1 |
Kawahara, T | 1 |
Sugiura, S | 1 |
Miyoshi, Y | 1 |
Teranishi, J | 1 |
Kosaka, T | 1 |
Miyajima, A | 1 |
Takayama, E | 1 |
Kikuchi, E | 1 |
Nakashima, J | 1 |
Ohigashi, T | 1 |
Asano, T | 1 |
Sakamoto, M | 1 |
Okita, H | 1 |
Murai, M | 1 |
Hayakawa, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase I Non-Randomized, Unblinded, Single-Center Trial of Oral Telmisartan Alone or Combined With Selected Standard of Care Therapies for Prostate Cancer[NCT06168487] | Early Phase 1 | 42 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for candesartan and Cancer of Prostate
Article | Year |
---|---|
[A novel molecular target therapeutics for refractory prostate cancer].
Topics: Alitretinoin; Androgens; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compoun | 2002 |
1 trial available for candesartan and Cancer of Prostate
Article | Year |
---|---|
Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Age | 2005 |
4 other studies available for candesartan and Cancer of Prostate
Article | Year |
---|---|
Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Cell Movemen | 2014 |
Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Biphenyl Com | 2012 |
Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Agents, Hormonal; Benzimidazoles; Biph | 2005 |
Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; | 2007 |